EVX-01 is a personalized, peptide-based neoantigen cancer immunotherapy addressing metastatic melanoma.

EVX-01 is our personalized cancer immunotherapy intended for the first-line treatment of metastatic and unresectable cancer patients. Each therapy is designed using our PIONEER platform and will engage each patient's immune system to fight off cancer by mounting a targeted response against tumors.

In the treatment of the patients we use our AI platform to find the most promising targets for the immunotherapy.

In the clinic with EVX-01

Data from the Phase 1/2a clinical trial of EVX-01 has shown that six of nine patients (67%) benefitted from EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®) for treating metastatic melanoma, compared to the historical data of only 33-40% benefitting from a PD-1 inhibitor alone.

What is even more encouraging is that 22% of the patients in the Phase 1/2a clinical trial achieved a complete response with EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®).

In addition, the data showed induction of neoantigen-specific T cells in 100% of patients. 76% of the administered neoantigens induced reactive T cells in patients, of which 83% were de novo responses.

Readout from our phase 1/2a clinical study has demonstrated that the EVX-01 therapy in combination with standard of care is well tolerated and able to induce neoantigen-dependent antitumor responses in patients, resulting in elimination or reduction in tumor burden.

Case: The photos above show one of the patients who achieved complete response following EVX-01 treatment.

Before (on the left): Enrollment scan showing the patient with stable disease after 10 months on Anti-PD1 (standard of care), prior to EVX-01 therapy. We can see the tumor marked in the red circle.

After (on the right): Scan following EVX-01 treatment showing complete response (complete elimination of tumor, no sign of cancer). The circle marks where the tumor was before treatment.